Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
about
Anti-nerve growth factor in pain management: current evidenceThe perception and endogenous modulation of painNerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain managementNeurotrophins and Neuropathic Pain: Role in PathobiologyA commentary on modelling osteoarthritis pain in small animalsOrthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor.Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain.Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-α stimulation of synovial cells: an in vitro study.Screening the role of pronociceptive molecules in a rodent model of endometriosis pain.Towards a mechanism-based approach to pain management in osteoarthritisFasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept studyTanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.Structural associations of symptomatic knee osteoarthritisLost but making progress--Where will new analgesic drugs come from?Reflecting on pain management for patients with osteoarthritis and other rheumatic disorders: there's more to pain management than managing painA canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated painDesign and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery.Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.Monoclonal antibodies for the treatment of osteoarthritis.Update on biological therapies for knee injuries: osteoarthritis.Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Intra-articular nerve growth factor regulates development, but not maintenance, of injury-induced facet joint pain & spinal neuronal hypersensitivity.A pain research agenda for the 21st century.Resiniferatoxin for Pain Treatment: An Interventional Approach to Personalized Pain Medicine.Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Clinical targeting of the TNF and TNFR superfamiliesChanges resembling complex regional pain syndrome following surgery and immobilization.Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administrationNerve Growth Factor Regulation by TNF-α and IL-1β in Synovial Macrophages and Fibroblasts in Osteoarthritic MiceThe fundamental unit of pain is the cell.Osteoarthritis: toward a comprehensive understanding of pathological mechanism.Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.Biologic agents in osteoarthritis: hopes and disappointments.Neurotrophins in bladder function: what do we know and where do we go from here?Nerve growth factor: an update on the science and therapy.Pro-neurotrophins, sortilin, and nociception.Mechanisms and Mediators That Drive Arthritis Pain.Skeletal complications in cancer patients with bone metastases.Tanezumab in the treatment of chronic musculoskeletal conditions.Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.
P2860
Q26746194-3928CB9F-45BF-4100-9EB8-206B299FEB52Q27011310-FEA39043-546F-441E-A461-D64628A305B1Q27011486-F95DEC06-AF7B-4A1F-863C-4CA3B40896E5Q28084413-D33485FF-E082-4721-AC0D-43AE911112AFQ30432076-B17A35C8-C4A6-42BF-8E4E-F555B9C39762Q30657180-1505CAD2-2BDE-4568-9673-16C36B98ADC1Q33610520-76486247-854E-4A4B-9B1C-0FAC73F3A72EQ33861852-4F1D2F18-2BB4-4B49-B77C-3E8869156BCBQ33989677-F35C60D1-5482-46C9-9420-6F6EC5F07C3DQ34120813-86698338-C278-486A-BE6C-5CCC36990665Q34140663-D64D9495-D0B7-40F7-85F6-BA47CEB94401Q34336925-18B7D498-1082-4F07-A25C-79F22CBFCF00Q35023177-13593FB8-1890-4315-8A5C-B7A083BB7ECBQ35058471-579C1EDB-8965-4028-BFF5-A60F4196FCD3Q35186476-5EE5E7FD-FAA6-4E41-A5A3-77A2E1B12A6BQ35568842-EDEEF7EE-5A81-4503-B0E4-434C5F08FC9AQ35858432-9B2A0E85-0E6E-442A-858A-D7760B17140CQ36050186-B4182DFD-3D00-43D8-B5DA-0CD67F2FF7E5Q36113839-BFF706DD-539A-4544-ADD7-81A40B7A49C0Q36130226-CDAF0925-68B4-41A3-BCF3-E3F58B67AD43Q36236043-E0268317-EB8D-4B2F-B652-9C64B52E0AF1Q36242561-24C73239-2866-48C1-BA4E-FD28D23C3C9EQ36332281-24413944-2F7F-4F62-B54E-7B1669816A26Q36458451-51211F51-BB9D-42F6-B2A9-E634D26826D8Q36706795-4DDF490E-4ED5-47D5-8CD7-A09ACBFF3ED8Q36762882-5A03538E-15AD-48D0-AD16-FF4081E523CEQ36816589-248A5F55-404E-49C3-987B-51D20C9F45C6Q36818355-9BF7E8B3-7672-4B2B-BB00-12B2D26D3F92Q37222995-9EF5A816-6570-4960-A27F-8091320A3864Q37381403-2099B5D8-6765-44C3-9E36-38C8B3DD0BA6Q37588803-DFA52719-A2A4-4359-B64B-9EEDEC882725Q37604491-499BCC3D-BD87-44A1-821C-39F44A3A5CC0Q38094906-2BE923DF-4773-474F-B565-06358655C56DQ38115263-74259326-A0CE-45EE-B5DC-764F136ADBD2Q38131207-D3D4BD34-A247-4B6D-BE7E-7991B6F5EE6FQ38185068-A38AAF9B-6ECD-4B92-B6AE-F332EEB5EC56Q38508116-F5627E6F-9011-4AEE-8EBA-1D2E724E0967Q38917438-94174F01-7D7F-443C-988E-F643FAA01641Q39034462-7CC73353-A188-4967-941B-BAFA290AB20EQ39195605-7C548D09-D8D9-4DDE-8272-020BB4F74B67
P2860
Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
type
label
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
prefLabel
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
P2093
P921
P1433
P1476
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
P2093
Christine R West
David M Radin
Frederick T Murphy
Isabelle Davignon
Mark T Brown
Michael D Smith
P304
P356
10.1016/J.JPAIN.2012.05.006
P577
2012-07-10T00:00:00Z